INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript

Core Insights - The presentation focuses on pivotal updates regarding the MissionEB Phase III clinical trial and the impact of CORDStrom on Recessive Dystrophic Epidermolysis Bullosa (RDEB) [1] Group 1: Company Overview - David Moss serves as the President, CEO, Treasurer, Secretary, and Director of INmune Bio, highlighting the company's leadership structure [1] - The event is being recorded and will be available on the company's YouTube channel later, indicating a commitment to transparency and communication with stakeholders [2] Group 2: Key Personnel - Dr. Mark Lowdell is introduced as the inventor of CORDStrom and a pioneer in cellular therapy, emphasizing his significant contributions to the development of advanced medicinal products [3] - Dr. Anna Martinez is the clinical lead for the MissionEB trial and a leading expert in the field of Epidermolysis Bullosa, showcasing the expertise driving the clinical program [4]